Belvedere Trading
RLMD icon

Belvedere Trading’s Relmada Therapeutics RLMD Stock Holding History

Belvedere Trading’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-13,200
Closed -$42.8K – 1013
2024
Q3 		$42.8K Buy
+13,200
New +$42.8K ﹤0.01% 543
2022
Q3 		– Sell
-15,400
Closed -$359K – 384
2022
Q2 		$359K Buy
15,400
+800
+5% +$17.4K 0.01% 117
2022
Q1 		$383K Buy
+14,600
New +$302K 0.01% 135

Other funds holding RLMD

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Belvedere Trading's RLMD Position: Q3 2024 in Review

Belvedere Trading sold out of Relmada Therapeutics (RLMD) in Q3 2024, closing a stake of 13,029 shares — an estimated $42.2K sold.

Belvedere Trading first reported a position in RLMD in Q3 2021 and held it in 4 quarters. The position peaked at $247K in Q3 2021. 69 funds tracked by Wall St. Rank hold RLMD as of Q3 2024.

  • Belvedere Trading reported no remaining Relmada Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Belvedere Trading sold 13,029 Relmada Therapeutics shares in Q3 2024, an estimated $42.2K.
  • Belvedere Trading first reported a position in Relmada Therapeutics in Q3 2021 and held it in 4 quarters.
  • Belvedere Trading's Relmada Therapeutics position peaked at $247K in Q3 2021.
  • 69 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q3 2024.

Based on Belvedere Trading's 13F filing for Q3 2024, filed 30 Oct 2024.